Morgan Stanley has published a research report on Teva Pharmaceuticals TEVA believing that 2012E guidance would have been higher had the Tricor battle not been lost.
In the report, Morgan Stanley writes, "We and consensus expected Teva to launch generic Tricor in July 2012 under the terms of Teva's Dec. 09 settlement with Abbott. We now believe Teva will forfeit exclusivity as FDA will not approve Teva's generic
formulation, per management. We believe TriCor would have added $0.15 in 2012, which in theory would have yielded a guidance midpoint of $5.73, 1% above cons' $5.67 (instead of midpoint of $5.58, 1.6% below cons)."
Morgan Stanley maintains its Overweight rating and $47 price target on Teva, which is currently trading down $0.57 from yesterday's $42.34 closing price.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in